Last reviewed · How we verify
trandolapril/verapamil
Trandolapril inhibits angiotensin-converting enzyme (ACE) to reduce blood pressure, while verapamil blocks calcium channels to slow heart rate and further lower blood pressure.
Trandolapril inhibits angiotensin-converting enzyme (ACE) to reduce blood pressure, while verapamil blocks calcium channels to slow heart rate and further lower blood pressure. Used for Hypertension, Angina pectoris.
At a glance
| Generic name | trandolapril/verapamil |
|---|---|
| Also known as | ABT-TARKA, Tarka, VeraTran |
| Sponsor | Abbott |
| Drug class | ACE inhibitor / calcium channel blocker combination |
| Target | Angiotensin-converting enzyme (ACE); L-type voltage-gated calcium channels |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
This combination drug pairs an ACE inhibitor (trandolapril) that prevents conversion of angiotensin I to angiotensin II with a non-dihydropyridine calcium channel blocker (verapamil) that reduces cardiac contractility and peripheral vascular resistance. Together, they provide complementary antihypertensive and cardioprotective effects, with verapamil also offering rate-control benefits in certain arrhythmias.
Approved indications
- Hypertension
- Angina pectoris
Common side effects
- Dizziness
- Headache
- Fatigue
- Constipation
- Cough
- Hyperkalemia
- Bradycardia
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Coronavirus (COVID-19) ACEi/ARB Investigation (PHASE4)
- Effectiveness and Patient Self-assessed Compliance of Blood Pressure Treatment With Tarka® Fixed Combination in Patients With Essential Hypertension
- INVEST: INternational VErapamil SR Trandolapril STudy (PHASE4)
- Effectiveness and Tolerability of Tarka® in the Treatment of Hypertensive Patients With High Risk of Developing Diabetes Mellitus
- Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients (TRAIL) (PHASE4)
- Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |